Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues

ObjectivesTo identify factors that contribute to variability of HSV antiviral susceptibility breakpoints.MethodsAcyclovir and penciclovir IC50's for 12 HSV clinical isolates were measured in two laboratories using plaque reduction assay (PRA), an enzyme immunoassay (EIA)-based antigen reduction, and DNA hybridization on Vero, A549, MRC-5, HEL299 and HELG monolayers. Pair-wise comparisons were performed to evaluate variables including testing laboratory, technique, monolayer, and antiviral. The proportion of false results was analyzed using a conventional susceptibility IC50 breakpoint of 2 μg/ml.ResultsAcyclovir-resistant HSV isolates were correctly identified by all methods. In contrast, there were 6–67% of susceptible isolates incorrectly characterized as drug-resistant. Variables associated with these errors included testing site, assay method, cell line and antiviral. A549, DNA hybridization, and penciclovir were associated with the highest IC50's, whereas the PRA, EIA, and human fibroblast-monolayers provided the best differentiation between susceptible and resistant HSV isolates.ConclusionsThe current recommendations to use a single discriminating value to define HSV resistance to nucleoside analogues can be problematic. False results are influenced in various degrees by the laboratory method, tissue culture and antivirals.